Explore the Limitless Potential of IL-18

Explore the Limitless Potential of IL-18

IL-18, also known as the IFN gamma-inducing factor, is a proinflammatory cytokine and a member of the IL-1 family. Initially, it is produced as an inactive pro-form and then secreted after maturation by caspase-1. IL-18 binds to the IL-18 receptor α (IL-18Rα) expressed on the surface of various cells, such as Kupffer cells, activated macrophages, keratinocytes, intestinal epithelial cells, osteoblasts, adrenal cortex cells, and murine diencephalon, leading to inflammation. IL-18 also acts on T helper type-1 (Th1) cells and, when combined with IL-12, strongly induces them to produce IFN-γ. IL-18 has pleiotropic effects, including enhancing the production of IFN-γ and GM-CSF in peripheral blood mononuclear cells and the production of Th1 cytokines IL-2, GM-CSF, and IFN-γ in T cells. It also enhances Fas ligand expression by Th1 cells. As a result, researchers are harnessing these regulatory processes for anti-tumour immune responses, as IL-18 enhances anti-tumour immunity in various cancer types. The potent activity of IL-18 in tumour models has underscored the significant potential of the IL-18 pathway as a target for tumour immunotherapy.

Researchers take advantage of MBL International’s recombinant IL-18 to activate varying cells like peripheral blood cells, macrophages, NK cells and T cells to identify targets.

For ex vivo studies, MBLI provides formulation without BSA. In addition, they offer other IL-18 products and are a trusted leader in IL-18 research worldwide. 

Product CodeProduct Name Size
B004-2Recombinant Mouse IL-18 (Without BSA)200 μg
B004-5Recombinant Mouse IL-18 (without BSA)25 μg
B003-5Recombinant Human IL-18 (without BSA)25 μg
B003-2Recombinant IL-18 (without BSA)200 μg


  1. Ohya, Takashi, et al. “Impaired Interleukin‐18 Signaling in Natural Killer Cells from Patients with Systemic Juvenile Idiopathic Arthritis.” ACR Open Rheumatology, vol. 4, no. 6, 2022, pp. 503–510., doi:10.1002/acr2.11426.
  2. Wang, Zhen, et al. “Interleukin-37 Promotes Colitis-Associated Carcinogenesis via SIGIRR-Mediated Cytotoxic T Cells Dysfunction.” Signal Transduction and Targeted Therapy, vol. 7, no. 1, 2022, doi:10.1038/s41392-021-00820-z.
  3. Tsutsuki, Hiroyasu, et al. “Subtilase Cytotoxin from Shiga-Toxigenic Escherichia Coli Impairs the Inflammasome and Exacerbates Enteropathogenic Bacterial Infection.” IScience, vol. 25, no. 4, 2022, p. 104050., doi:10.1016/j.isci.2022.104050.
  4. Stone, Deborah L., et al. “Excess Serum Interleukin‐18 Distinguishes Patients with Pathogenic Mutations in pstpip1 .” Arthritis & Rheumatology, vol. 74, no. 2, 2022, pp. 353–357., doi:10.1002/art.41976.

Information provided by MBL.

Caltag Medsystems is the distributor of MBL products in the UK and Ireland. If you have any questions about these products, please contact us.

Explore the Limitless Potential of IL-18
Tagged on:         

Contact us